Cargando…

Utilization of Existing Human Kinase Inhibitors as Scaffolds in the Development of New Antimicrobials

The prevalence and continuing expansion of drug resistance, both in clinical and community settings represents a major challenge for current antimicrobial therapy. The different approaches for addressing this challenge include (1) identification of novel antibacterials by repurposing of existing dru...

Descripción completa

Detalles Bibliográficos
Autores principales: Konaklieva, Monika I., Plotkin, Balbina J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10525673/
https://www.ncbi.nlm.nih.gov/pubmed/37760715
http://dx.doi.org/10.3390/antibiotics12091418
_version_ 1785110840733597696
author Konaklieva, Monika I.
Plotkin, Balbina J.
author_facet Konaklieva, Monika I.
Plotkin, Balbina J.
author_sort Konaklieva, Monika I.
collection PubMed
description The prevalence and continuing expansion of drug resistance, both in clinical and community settings represents a major challenge for current antimicrobial therapy. The different approaches for addressing this challenge include (1) identification of novel antibacterials by repurposing of existing drugs originally that historically target host proteins; and (2) effect target switching through modification of existing antimicrobials. The focus of this manuscript is on these drug discovery strategies, with utility for development of new antimicrobials with different modes of action.
format Online
Article
Text
id pubmed-10525673
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-105256732023-09-28 Utilization of Existing Human Kinase Inhibitors as Scaffolds in the Development of New Antimicrobials Konaklieva, Monika I. Plotkin, Balbina J. Antibiotics (Basel) Review The prevalence and continuing expansion of drug resistance, both in clinical and community settings represents a major challenge for current antimicrobial therapy. The different approaches for addressing this challenge include (1) identification of novel antibacterials by repurposing of existing drugs originally that historically target host proteins; and (2) effect target switching through modification of existing antimicrobials. The focus of this manuscript is on these drug discovery strategies, with utility for development of new antimicrobials with different modes of action. MDPI 2023-09-07 /pmc/articles/PMC10525673/ /pubmed/37760715 http://dx.doi.org/10.3390/antibiotics12091418 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Konaklieva, Monika I.
Plotkin, Balbina J.
Utilization of Existing Human Kinase Inhibitors as Scaffolds in the Development of New Antimicrobials
title Utilization of Existing Human Kinase Inhibitors as Scaffolds in the Development of New Antimicrobials
title_full Utilization of Existing Human Kinase Inhibitors as Scaffolds in the Development of New Antimicrobials
title_fullStr Utilization of Existing Human Kinase Inhibitors as Scaffolds in the Development of New Antimicrobials
title_full_unstemmed Utilization of Existing Human Kinase Inhibitors as Scaffolds in the Development of New Antimicrobials
title_short Utilization of Existing Human Kinase Inhibitors as Scaffolds in the Development of New Antimicrobials
title_sort utilization of existing human kinase inhibitors as scaffolds in the development of new antimicrobials
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10525673/
https://www.ncbi.nlm.nih.gov/pubmed/37760715
http://dx.doi.org/10.3390/antibiotics12091418
work_keys_str_mv AT konaklievamonikai utilizationofexistinghumankinaseinhibitorsasscaffoldsinthedevelopmentofnewantimicrobials
AT plotkinbalbinaj utilizationofexistinghumankinaseinhibitorsasscaffoldsinthedevelopmentofnewantimicrobials